<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-0793</journal-id>
<journal-title><![CDATA[Iatreia]]></journal-title>
<abbrev-journal-title><![CDATA[Iatreia]]></abbrev-journal-title>
<issn>0121-0793</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Antioquia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-07932008000100005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Toxicidad hepática por medicamentos antituberculosos]]></article-title>
<article-title xml:lang="en"><![CDATA[Hepatotoxicity induced by antituberculosis drugs]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez Calzada]]></surname>
<given-names><![CDATA[Ubier Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Agudelo Berruecos]]></surname>
<given-names><![CDATA[Yuli]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Berrouet Mejía]]></surname>
<given-names><![CDATA[Marie Claire]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escobar Toledo]]></surname>
<given-names><![CDATA[Isabel Eugenia]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad de Antioquia Facultad de Medicina Departamento de Farmacología y Toxicología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidad de Antioquia Facultad de Medicina Departamento de Farmacología y Toxicología]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Universidad de Antioquia Facultad de Medicina Departamento de Farmacología y Toxicología]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2008</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2008</year>
</pub-date>
<volume>21</volume>
<numero>1</numero>
<fpage>41</fpage>
<lpage>48</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-07932008000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-07932008000100005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-07932008000100005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[El fenómeno de la toxicidad hepática inducida por medicamentos cobró relevancia hace algunos años con el estudio de las reacciones adversas a medicamentos. El daño producido en el hígado por un xenobiótico que altera su función es lo que se conoce como toxicidad hepática. La importancia de reconocer y diagnosticar la toxicidad hepática por medicamentos estriba en su gravedad potencial; no en vano es la causa más frecuente por la que la industria farmacéutica retira medicamentos. La tuberculosis es una pandemia que afecta a gran parte de la población mundial y junto con el VIH es una enfermedad cada vez más frecuente en Colombia. Esta enfermedad se puede considerar como una situación especial porque para su tratamiento es preciso suministrar, por largos períodos, medicamentos con potencial tóxico para el hígado. El objetivo de este artículo es revisar algunos aspectos relacionados con la toxicidad hepática secundaria a medicamentos antituberculosos, tales como: epidemiología, factores de riesgo, mecanismos de toxicidad, manifestaciones clínicas, diagnóstico, tratamiento y seguimiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Hepatotoxicity is the alteration of liver structure and function induced by either drugs or other substances. The importance of its proper diagnosis rests on its potential severity. It is the most frequent reason by which the pharmaceutical industry withdraws its products. Tuberculosis is a pandemic infection affecting a large proportion of the world population. Together with HIV infection it is becoming ever more frequent in Colombia. Tuberculosis poses a special challenge because its treatment requires the administration, during long periods, of drugs with the potential of inducing liver injury. In this article some aspects of hepatotoxicity induced by antituberculosis drugs are reviewed, namely: epidemiology, risk factors, mechanisms, clinical manifestations, diagnosis, treatment and follow-up.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Factores de riesgo para toxicidad hepática]]></kwd>
<kwd lng="es"><![CDATA[Mecanismos de toxicidad hepática]]></kwd>
<kwd lng="es"><![CDATA[Medicamentos antituberculosos]]></kwd>
<kwd lng="es"><![CDATA[Reintroducción del tratamiento antituberculoso]]></kwd>
<kwd lng="es"><![CDATA[Toxicidad hepática]]></kwd>
<kwd lng="en"><![CDATA[Antituberculosis drugs]]></kwd>
<kwd lng="en"><![CDATA[Hepatotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Hepatotoxicity mechanisms]]></kwd>
<kwd lng="en"><![CDATA[Reintroduction of antituberculosis treatment]]></kwd>
<kwd lng="en"><![CDATA[Risk factors for hepatotoxicity]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[IR]]></given-names>
</name>
<name>
<surname><![CDATA[Aronson]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Adverse drug reactions: definitions, diagnosis and management]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<numero>9237</numero>
<issue>9237</issue>
<page-range>1212</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larrey]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epidemiology and individual susceptibility to adverse drug reactions affecting the liver]]></article-title>
<source><![CDATA[Semin Liver Dis]]></source>
<year>2002</year>
<volume>22</volume>
<page-range>145-155</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sgro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Clinard]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Quazir]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Incidence of drug-induced hepatic injuries: A French population-based study]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2002</year>
<volume>36</volume>
<page-range>451-455</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zimmerman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ishak]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[General aspects of drug-induced liver disease]]></article-title>
<source><![CDATA[Gastroenterol Clin N Am]]></source>
<year>1995</year>
<volume>24</volume>
<page-range>739-757</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trey]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The management of fulminant hepatic failure]]></article-title>
<source><![CDATA[Prog Liver Dis]]></source>
<year>1970</year>
<volume>3</volume>
<page-range>282-298</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ostapowicz]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schiodt]]></surname>
<given-names><![CDATA[FV]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Davern]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2002</year>
<volume>137</volume>
<page-range>947-954</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Drug related hepatotoxicity]]></article-title>
<source><![CDATA[New Engl J Med]]></source>
<year>2006</year>
<volume>354</volume>
<page-range>731-739</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<source><![CDATA[Global tuberculosis control: surveillance, planning, financing]]></source>
<year></year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lucena]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pelaez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pachkoria]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[García-Ruiz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[On behalf of the Spanish group for the Study of Drug-Induced Liver Disease: Toxic and drug-induced liver injury: an analysis of 461 incidences submitted to a Registry over a 10-year period]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2005</year>
<volume>129</volume>
<page-range>512-521</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="confpro">
<collab>FDA Working Group</collab>
<source><![CDATA[]]></source>
<year>Nove</year>
<month>mb</month>
<day>er</day>
<conf-name><![CDATA[ Clinical White paper on drug-induced hepatotoxicity]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gülbay]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Gürkan]]></surname>
<given-names><![CDATA[OU]]></given-names>
</name>
<name>
<surname><![CDATA[Yildiz]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
<name>
<surname><![CDATA[Onen]]></surname>
<given-names><![CDATA[ZP]]></given-names>
</name>
<name>
<surname><![CDATA[Erkekol]]></surname>
<given-names><![CDATA[FO]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>2006</year>
<volume>100</volume>
<page-range>1834-1842</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thiim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatotoxicity of antibiotics and antifungals]]></article-title>
<source><![CDATA[Clin Liver Dis]]></source>
<year>2003</year>
<volume>7</volume>
<page-range>381-399</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hepatotoxicidad por fármacos antituberculosos en Pediatría]]></article-title>
<source><![CDATA[Rev Gastroenterol Perú]]></source>
<year>2005</year>
<volume>25</volume>
<page-range>362-365</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Drug-induced hepatotoxicity]]></article-title>
<source><![CDATA[New Engl J Med]]></source>
<year>1995</year>
<volume>17</volume>
<page-range>1118-1127</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Camargo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lucena]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[González-Grande]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Causality assessment in drug-induced hepatotoxicity]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2004</year>
<volume>3</volume>
<page-range>329-344</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benichou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Criteria of drug-induced liver disorders: report of an international consensus meeting]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>1990</year>
<volume>11</volume>
<page-range>272-276</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Valiquette]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Pelletier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parisien]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rocher]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2003</year>
<volume>167</volume>
<page-range>1472-1477</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Physiological factors affecting drug toxicity]]></article-title>
<source><![CDATA[Regul Toxicol Pharmacol]]></source>
<year>1983</year>
<volume>3</volume>
<page-range>389-398</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schaberg]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rebhan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lode]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk factors for sideeffects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>1996</year>
<volume>9</volume>
<page-range>2026-2030</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaima]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antituberculosis drugs and hepatotoxicity]]></article-title>
<source><![CDATA[Infect Genet Evol]]></source>
<year>2004</year>
<volume>4</volume>
<page-range>167-170</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santhosh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of chitosan supplementation on antitubercular drugs-induced hepatotoxicity in rats]]></article-title>
<source><![CDATA[Toxicology]]></source>
<year>2006</year>
<volume>219</volume>
<page-range>53-59</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Troy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A model of isoniazid-induced hepatotoxicity in rabbits]]></article-title>
<source><![CDATA[J Pharmacol Toxicol Methods]]></source>
<year>1995</year>
<volume>34</volume>
<page-range>109-116</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Attri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rana]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Isoniazid and rifampicin induced oxidative hepatic- injury protection by NAC]]></article-title>
<source><![CDATA[Hum Exp Toxicol]]></source>
<year>2000</year>
<volume>19</volume>
<page-range>517-522</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prabakan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Protective effect of Hemidesmus indicus against rifampicin and isoniazid induced hepatotoxicity in rats]]></article-title>
<source><![CDATA[Fitotherapy]]></source>
<year>2000</year>
<volume>71</volume>
<page-range>55-59</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corbella]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Vadillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hipersensitivity hepatitis due to pyrazinamide]]></article-title>
<source><![CDATA[Scand J Infect Dis]]></source>
<year>1995</year>
<volume>27</volume>
<page-range>93-94</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chowdhury]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2006</year>
<volume>45</volume>
<page-range>116-123</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Antihepatotoxic activity of monomethil fumarate isolated from Fumaria indica]]></article-title>
<source><![CDATA[Etnopharmacology]]></source>
<year>1998</year>
<volume>60</volume>
<page-range>207-213</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
